Yeah, they seem to be patting themselves on the back for this result (probably YoY) whereas you guys are understandably dissapointed by the QoQ fall. But guys we saw this lumpiness last year, again with no real explanation - bar this time the facilities in the "clean room" being shut down (and what we know of HenrySchein's outage). These guys are good on shouting out the approvals and deals, but the organic running of the business never been well clarified.
The sales team has never earnt its costs in a decade of operation (admittedly with hard products to push pre-approval). I think underperformance in the sales teams (given expenses) now that Striate and Remplir approved (the latter in AUS only until next year) is no longer forgiveable. But they are looking at quarter to quarter YoY, and technically they are kind of correct:
"Increasing revenue driven by growth in new product sales." Last year 3Q 23FY sales resceipts were $265K, so they increased sales 143% for the quarter on a YoY comparison - undeniably good, but from a low dip last year. I always keep a running yearly tally to take out lumpiness, that I have posted before. The best perspective for these figures until we get some explanation on 3Q lumpiness:
Qtr
4C Receipts
YoY(QTr)
QoQ
TYCS
%TYCS
Man. costs
MC Chge (%)
1
1QFY21
179
2
2QFY21
218
22%
3
3QFY21
206
-6%
4
4QFY21
325
58%
928
5
1QFY22
356
99%
10%
1105
6
2QFY22
378
73%
6%
1265
7
3QFY22
313
52%
-17%
1372
8
4QFY22
407
25%
30%
1454
57%
0
9
1QFY23
463
30%
14%
1561
41%
316
#DIV/0!
10
2QFY23
500
32%
8%
1683
33%
604
91%
11
3QFY23
265
-15%
-47%
1635
19%
520
-14%
12
4QFY23
645
58%
143%
1873
29%
746
43%
13
1QFY24
898
94%
39%
2308
48%
360
-52%
14
2QFY24
896
79%
0%
2704
61%
522
45%
15
3QFY24
645
143%
-28%
3084
89%
522
0%
TYCS is the trailing yearly cash sales - basically the last quarters combined. I am not complementing these guys, the sales growth is not good enough for me, but we always see 3Q drops in cash receipts across the January holiday period (when most Surgeons I know, off skiing in Vail or Aspen) and allowing for that lumpiness, the company is right; sales are growing strongly, vs last year the trailing yearly cash receipts are +89%.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.